Webinar: Strategies for In-House Counsel Selecting Trademarks for Pharmaceuticals and Biologics
Naming pharmaceutical and biologic products presents unique challenges from both trademark and regulatory perspectives. In addition to the traditional marketing goals of trademark selection, companies evaluating names for medications must also consider safety issues, false advertising concerns, and more. Importantly, pharmaceutical trademarks must pass muster not only with the Patent and Trademark Office (PTO), but also with the Food and Drug Administration (FDA). The recent advent of a market for biosimilars presents new questions and challenges.
Foley Hoag will present a 60-minute webinar on Wednesday, January 25, 2017 at 12:30 pm EST offering guidance to in-house counsel on best practices for pharmaceutical and biologics companies in selecting, vetting, and seeking approval for medication product names. The focus will be primarily on the U.S. market, although foreign strategies may be addressed as well.
Topics to be discussed
- Trademark basics from a pharmaceutical perspective
- Importance of trademarks for a pharmaceutical product’s value proposition
- PTO application process and approval standards
- FDA application process and approval standards
- Recommended approach to selecting and securing rights in pharmaceutical/biologic trademarks
- Special considerations for the new biosimilars space
- Examples of successful approval/application strategies
- Julia Huston, Partner, Chair, Trademark, Copyright & Unfair Competition Practice, Foley Hoag LLP - Boston